Levosulpiride for Premature Ejaculation: A Systematic Review and Meta-Analysis

Area of Science:

• Urology
• Sexual Medicine
• Pharmacology

Background:

• Premature ejaculation (PE) is a common sexual dysfunction impacting quality of life.
• Levosulpiride is an off-label medication considered for PE treatment.
• Evidence regarding levosulpiride's efficacy for PE is limited.

Purpose of the Study:

• To systematically review and meta-analyze the efficacy of levosulpiride in treating premature ejaculation.
• To assess the impact of levosulpiride on intravaginal ejaculation latency time (IELT).

Main Methods:

• Systematic review and meta-analysis of randomized control trials (RCTs).
• Searched PubMed, Science Direct, and Google Scholar for relevant studies.
• Calculated odds ratios (OR) for improved IELT compared to placebo.

Main Results:

• Four RCTs with 203 men were included; two were used for meta-analysis.
• Levosulpiride significantly increased the odds of improved IELT (OR: 100.81, p < .05).
• Significant improvements in IELT were observed for >5 min (OR: 38.88) and 1-5 min (OR: 32.84) durations (p < .05).

Conclusions:

• Levosulpiride demonstrates significant efficacy in improving IELT for men with PE.
• The current evidence base is limited, with identified selection and detection bias.
• Further high-quality research is essential to validate these preliminary findings and guide clinical practice.